Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Theravance Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TBPH
Nasdaq
2834
https://www.theravance.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Theravance Biopharma Inc
BTIG Research Predicts Over 118% Rally for These 3 Stocks
- Apr 15th, 2024 6:19 pm
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
- Apr 15th, 2024 11:47 am
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
- Apr 10th, 2024 10:00 am
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
- Apr 3rd, 2024 3:30 pm
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
- Mar 27th, 2024 3:30 pm
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
- Mar 12th, 2024 7:59 pm
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 3:35 pm
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
- Feb 27th, 2024 4:47 pm
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
- Feb 26th, 2024 10:25 pm
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 26th, 2024 9:05 pm
Theravance Biopharma to Participate in an Upcoming Investor Conference
- Feb 22nd, 2024 11:00 am
Will Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?
- Feb 15th, 2024 12:07 pm
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Feb 14th, 2024 11:00 am
Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long
- Jan 19th, 2024 10:59 am
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
- Jan 12th, 2024 2:35 pm
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Jan 5th, 2024 11:00 am
7 Short-Squeeze Stocks That Are Screaming for Speculation
- Dec 24th, 2023 6:08 pm
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
- Dec 21st, 2023 10:00 pm
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
- Dec 18th, 2023 11:00 am
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable
- Dec 9th, 2023 1:35 pm
Scroll